Vtama in Psoriasis Patients Being Treated With Biologics.

Psoriasis Clinical Trial

Official title:

Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06103695
• Other study ID #: PTC10
• Status: Completed
• Phase: Phase 4
• Start date: February 27, 2023
• Est. completion date: October 18, 2023

Study information

• Verified date: October 2023
• Source: Psoriasis Treatment Center of Central New Jersey
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 18, 2023
• Est. primary completion date: October 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female adult = 18 years of age;

2. Diagnosis of chronic plaque-type

3. Patient with =3% BSA

4. Patient has been treated with biologic for a minimum of 24 weeks

5. Able and willing to give written informed consent prior to performance of any study-related procedures.

Exclusion Criteria:

1. =3% BSA

2. Patient not receiving biologic agent, or receiving biologic agent <24weeks

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• Tapinarof
Add on Vtama (tapinarof) to biololgic therapy

Locations

Country	Name	City	State
United States	Schweiger Derm Group	East Windsor	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Psoriasis Treatment Center of Central New Jersey

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Body surface area =1%	Patients who achieve body surface area of =1%	12 weeks